Merus NV. Daily Stock Analysis

Daily Stock Analysis, MRUS, Merus NV, priceseries

Merus NV. Daily Stock Analysis
Stock Information
Open
26.17
Close
25.68
High
27.06
Low
25.18
Previous Close
26.43
Daily Price Gain
-0.75
YTD High
32.37
YTD High Date
Jan 3, 2022
YTD Low
22.22
YTD Low Date
Jan 28, 2022
YTD Price Change
-5.23
YTD Gain
-16.92%
52 Week High
33.09
52 Week High Date
Dec 31, 2021
52 Week Low
16.14
52 Week Low Date
Jul 27, 2021
52 Week Price Change
3.02
52 Week Gain
13.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 1. 2017
25.93
Mar 20. 2017
28.63
13 Trading Days
10.40%
Link
LONG
Sep 15. 2017
15.93
Oct 17. 2017
20.69
22 Trading Days
29.91%
Link
LONG
Dec 26. 2017
15.26
Jan 2. 2018
16.29
4 Trading Days
6.78%
Link
LONG
Jun 6. 2018
18.84
Jun 25. 2018
20.90
13 Trading Days
10.94%
Link
LONG
Jun 29. 2018
22.76
Jul 16. 2018
24.43
10 Trading Days
7.34%
Link
LONG
Feb 27. 2019
11.59
Mar 8. 2019
12.43
7 Trading Days
7.27%
Link
LONG
Apr 10. 2019
13.56
Apr 17. 2019
14.29
5 Trading Days
5.40%
Link
LONG
Jan 13. 2020
14.90
Jan 31. 2020
16.38
13 Trading Days
9.91%
Link
LONG
Apr 22. 2020
14.37
Apr 28. 2020
15.12
4 Trading Days
5.20%
Link
LONG
Nov 16. 2020
13.65
Dec 14. 2020
16.88
19 Trading Days
23.64%
Link
LONG
Jan 15. 2021
23.31
Feb 2. 2021
25.52
11 Trading Days
9.48%
Link
LONG
Aug 19. 2021
22.02
Sep 8. 2021
25.18
13 Trading Days
14.35%
Link
LONG
Dec 7. 2021
26.24
Jan 3. 2022
30.72
18 Trading Days
17.06%
Link
Company Information
Stock Symbol
MRUS
Exchange
NasdaqGM
Company URL
http://www.merus.nl
Company Phone
31 030 253 8800
CEO
Ton Logtenberg
Headquarters
-
Business Address
YALELAAN 62, 3584 CM UTRECHT, NETHERLANDS 3584 CM
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001651311
About

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Description

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading